Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children

Polat M., Kara S. S.

INFECTION AND DRUG RESISTANCE, cilt.10, ss.393-399, 2017 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 10
  • Basım Tarihi: 2017
  • Doi Numarası: 10.2147/idr.s148703
  • Dergi Adı: INFECTION AND DRUG RESISTANCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.393-399
  • Anahtar Kelimeler: amikacin, children, community-acquired urinary tract infections, Escherichia coli, extended-spectrum beta-lactamase, outpatient, RESISTANCE TRENDS SMART, ANTIMICROBIAL RESISTANCE, KLEBSIELLA-PNEUMONIAE, MULTIDRUG-RESISTANT, THERAPY, ENTEROBACTERIACEAE, BACTERIA, SUSCEPTIBILITY, EFFICACY
  • Gazi Üniversitesi Adresli: Hayır

Özet

Background: The rise in community-acquired urinary tract infections (UTIs) with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli strains raises the question of how to treat these infections effectively in pediatric outpatients. Amikacin has shown promising in vitro activity against ESBL-producing urinary isolates of E. coli; however, clinical data are limited.